BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 49270)

  • 21. The treatment of Hodgkin's disease.
    Fairley GH
    Trans Med Soc Lond; 1972; 88():61-71. PubMed ID: 4665820
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy.
    Cannellos GP; Young RC; DeVita VT
    Clin Pharmacol Ther; 1972; 13(5):750-4. PubMed ID: 5053816
    [No Abstract]   [Full Text] [Related]  

  • 23. [Polychemotherapy in generalized form of Hodgkin's disease].
    van Hove W; Hamers J; Baele G; Vermeulen A
    Acta Clin Belg; 1975; 30(4):277-82. PubMed ID: 1211048
    [No Abstract]   [Full Text] [Related]  

  • 24. The management of advanced Hodgkin's disease.
    Young CW
    Clin Bull; 1975; 5(3):102-5. PubMed ID: 1227736
    [No Abstract]   [Full Text] [Related]  

  • 25. ABVD treatment of MOPP failures in Hodgkin's disease: a re-examination of goals of salvage therapy.
    Clamon GH; Corder MP
    Cancer Treat Rep; 1978 Mar; 62(3):363-7. PubMed ID: 77188
    [No Abstract]   [Full Text] [Related]  

  • 26. Sequential radiotherapy and chemotherapy in the treatment of Hodgkin's disease. A progress report.
    Moore MR; Bull JM; Jones SE; Rosenberg SA; Kaplan HS
    Ann Intern Med; 1972 Jul; 77(1):1-9. PubMed ID: 5052446
    [No Abstract]   [Full Text] [Related]  

  • 27. [On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
    Brunner KW; Maurice P; Sonntag RW
    Schweiz Med Wochenschr; 1972 Oct; 102(43):1546-51. PubMed ID: 4647016
    [No Abstract]   [Full Text] [Related]  

  • 28. [Cytostatic chemotherapy in lymphogranulomatosis].
    Stacher A
    Med Klin; 1973 Jul; 68(30):985-8. PubMed ID: 4131695
    [No Abstract]   [Full Text] [Related]  

  • 29. Long-term outcome of children and adolescents treated with the COPP-ABV hybrid protocol for Hodgkin's disease: balance of risks.
    Klumb CE; Carriço MK; de Rezende LM; Byington R; Bordallo MA; Bigni RS; Apa AG; Dobbin JA
    Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):628-9. PubMed ID: 17662581
    [No Abstract]   [Full Text] [Related]  

  • 30. [Polychemotherapy of Hodgkin's lymphoma. 3. Stage IV].
    Lauria F; Baccarani M; Bagnara GP; Gugliotta L; Ricci P; Santucci MA; Tura S
    Haematologica; 1972; 57(9):536-42. PubMed ID: 4199308
    [No Abstract]   [Full Text] [Related]  

  • 31. Pediatric Hodgkin's disease.
    Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
    J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Greater curability in advanced Hodgkin's disease?
    Portlock CS
    Cancer J Sci Am; 1999; 5(5):264-5. PubMed ID: 10526665
    [No Abstract]   [Full Text] [Related]  

  • 33. Chemotherapy oif childhood Hodgkin's disease in Uganda.
    Ziegler JL; Fass L; Bluming AZ; Magrath IT; Templeton AC
    Lancet; 1972 Sep; 2(7779):679-82. PubMed ID: 4115819
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of Hodgkin's disease. Experience of the Hôpital Saint-Louis].
    Boiron M; Teillet F; Weisgerber C; Dana M; Jacquillat C; Bernard J
    Rev Prat; 1974 Oct; 24(45):3971-8. PubMed ID: 4445767
    [No Abstract]   [Full Text] [Related]  

  • 35. [Cytostatic chemotherapy of lymphogranulomatosis].
    Dold U
    Dtsch Med Wochenschr; 1978 Feb; 103(6):235-8. PubMed ID: 75085
    [No Abstract]   [Full Text] [Related]  

  • 36. Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy.
    Arseneau JC; Sponzo RW; Levin DL; Schnipper LE; Bonner H; Young RC; Canellos GP; Johnson RE; DeVita VT
    N Engl J Med; 1972 Nov; 287(22):1119-22. PubMed ID: 5082192
    [No Abstract]   [Full Text] [Related]  

  • 37. Combination chemotherapy with nitrogen mustard, vincristine, procarbazine and prednisone in previously treated patients with Hodgkin's disease.
    Lowenbraun S; DeVita VT; Serpick AA
    Blood; 1970 Dec; 36(6):704-17. PubMed ID: 5488687
    [No Abstract]   [Full Text] [Related]  

  • 38. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABDV).
    Case DC; Young CW; Lee BJ
    Cancer; 1977 Apr; 39(4):1382-6. PubMed ID: 66972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure.
    Porzig KJ; Portlock CS; Robertson A; Rosenberg SA
    Cancer; 1978 May; 41(5):1670-5. PubMed ID: 77180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.